Iambic, an AI-focused drug discovery company with multiple big-pharma partnerships, said its planned IPO will help fund an internal oncology pipeline led by IAM1363, a Phase I/Ib HER2 inhibitor that has shown anti-tumour activity in heavily pretreated patients with HER2-altered solid tumours. The company also said it plans a registrational trial for IAM1363 next year and IND filings in the fourth quarter for two additional preclinical cancer programmes.

Why It Matters To Oncology

• Iambic is trying to convert AI-enabled discovery revenue into internally owned oncology assets, a closely watched model for clinicians and drug developers.

• Its lead candidate, IAM1363, is an oral, brain-penetrant small-molecule HER2 inhibitor in Phase I/Ib testing for HER2-altered solid tumours.

• The company has reported anti-tumour activity in heavily pretreated patients across tumour types including non-small-cell lung, breast, gastric, renal, ovarian and other HER2-driven cancers.

• IAM217, a brain-penetrant allosteric KIF18A inhibitor, is being developed for ovarian cancer, triple-negative breast cancer and other solid tumours, while IAM-C1 targets HR-positive, HER2-negative breast cancer.

The Financials

• Iambic disclosed its IPO plans shortly after announcing a new discovery collaboration with AbbVie.

• Earlier this year, it also signed deals with Takeda and Bayer; the Takeda agreement is worth up to $1.7 billion and includes oncology, gastrointestinal and inflammatory diseases.

• The company said partnership income has supported operations so far, but proceeds from a public offering are expected to help advance its own pipeline.

• Iambic added that some IPO proceeds could also be used for acquisitions or investments in products, services or technologies.

What They're Saying

• Iambic says its Enchant v3 platform can integrate assay data, molecular and protein structures, multi-omics and pharmacokinetics to predict candidate properties and compare drug-design strategies.

• In its securities filing, the company said IAM1363 is the only HER2 tyrosine kinase inhibitor that binds the inactive conformation of the HER2 kinase domain.

• That mechanism, Iambic argues, may support selectivity for HER2 over wild-type EGFR and broad activity across HER2 variants with activating mutations.

• NVIDIA, which is also collaborating with Iambic to optimise AI models, holds a stake of more than 5%, according to the filing.

What's Next

• Iambic plans to begin a registrational trial for IAM1363 in 2027.

• The company is also studying IAM1363 with Jazz Pharmaceuticals' bispecific HER2 antibody zanidatamab in heavily pretreated HER2-positive breast cancer.

• IND filings for IAM217 and IAM-C1 are planned in the fourth quarter.

• For oncology clinicians, the near-term watch points are durability and breadth of HER2 activity, CNS relevance, combination data and whether AI-enabled discovery can translate into registrational success.